版本:
中国

BRIEF-Regeneron and Sanofi announce FDA approval of Dupixent

March 28 Sanofi SA :

* Regeneron and Sanofi announce FDA approval of Dupixent® (Dupilumab), the first targeted biologic therapy for adults with moderate-to-severe atopic dermatitis

* Dupixent is expected to be available to patients and providers in U.S. later this week

* Regeneron and Sanofi Genzyme, specialty care global business unit of Sanofi, will market Dupixent in United States Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐